<DOC>
	<DOC>NCT00667589</DOC>
	<brief_summary>The purpose of this study is to evaluate treatments for a rash caused by sorafenib.</brief_summary>
	<brief_title>Sorafenib-induced Hand- Foot Skin Reaction Treatment</brief_title>
	<detailed_description>This study will compare compare the effectiveness of four creams (urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, and Udderly smoothÂ® Udder Cream) in treating hand-foot skin reaction (HFSR), a rash caused by sorafenib.</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Fluocinonide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<mesh_term>Emollients</mesh_term>
	<criteria>Patients receiving sorafenib as monotherapy or in combination if other agents are not known to cause HFSR. Subjects must be 18 years or older. Patients must provide written informed consent to participate in the study. Women of childbearing potential and men must be willing to use an effective method of contraception while participating in this study and for at least two weeks after completing treatment in the study. Women in this study need to have a negative urine pregnancy test before starting study medications. Patients simultaneously taking another anticancer agent or combination of anticancer agents known to cause hand foot syndrome (pegylated doxorubicin, 5fluorouracil, cytarabine). Patients with an active dermatological condition due to previous chemotherapy or biologic therapy affecting the hands. Patients with preexisting dermatological condition affecting the hands or feet. Women who have a positive pregnancy test or are lactating.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>sorafenib</keyword>
	<keyword>rash</keyword>
	<keyword>hand foot skin reaction</keyword>
</DOC>